Show simple item record

dc.contributor.authorAwad, Mark M.en_US
dc.contributor.authorMastini, Cristinaen_US
dc.contributor.authorBlasco, Rafael B.en_US
dc.contributor.authorMologni, Lucaen_US
dc.contributor.authorVoena, Claudiaen_US
dc.contributor.authorMussolin, Laraen_US
dc.contributor.authorMach, Stacy L.en_US
dc.contributor.authorAdeni, Anika E.en_US
dc.contributor.authorLydon, Christine A.en_US
dc.contributor.authorSholl, Lynette M.en_US
dc.contributor.authorJänne, Pasi A.en_US
dc.contributor.authorChiarle, Robertoen_US
dc.date.accessioned2017-12-06T16:20:21Z
dc.date.issued2017en_US
dc.identifier.citationAwad, M. M., C. Mastini, R. B. Blasco, L. Mologni, C. Voena, L. Mussolin, S. L. Mach, et al. 2017. “Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.” Oncotarget 8 (54): 92265-92274. doi:10.18632/oncotarget.21182. http://dx.doi.org/10.18632/oncotarget.21182.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34493175
dc.description.abstractThe anaplastic lymphoma kinase (ALK) is recognized by the immune system as a tumor antigen, and preclinical evidence suggests that ALK-rearranged NSCLCs can also be successfully targeted immunologically using vaccine-based approaches. In contrast to ALK-rearranged lymphomas, the frequency and clinical significance of spontaneous ALK immune responses in patients with ALK-rearranged NSCLCs are largely unknown. We developed an enzyme-linked immunosorbent assay (ELISA) to measure anti-ALK antibody levels and mapped specific peptide epitope sequences within the ALK cytoplasmic domain in patients with non-small cell lung cancer. The ELISA method showed good correlation with ALK antibody titers measured with a standard immunocytochemical approach. Strong anti-ALK antibody responses were detected in 9 of 53 (17.0%) ALK-positive NSCLC patients and in 0 of 38 (0%) ALK-negative NSCLC patients (P<0.01), and the mean antibody levels were significantly higher in ALK-positive than in ALK-negative NSCLC patients (P=0.02). Across individual patients, autoantibodies recognized different epitopes in the ALK cytoplasmic domain, most of which clustered outside the tyrosine kinase domain. Whether the presence of high ALK autoantibody levels confers a more favorable prognosis in this patient population warrants further investigation.en
dc.language.isoen_USen
dc.publisherImpact Journals LLCen
dc.relation.isversionofdoi:10.18632/oncotarget.21182en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696179/pdf/en
dash.licenseLAAen_US
dc.subjectlung canceren
dc.subjectanaplastic lymphoma kinaseen
dc.subjectautoantibodiesen
dc.subjectimmunotherapyen
dc.titleEpitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung canceren
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOncotargeten
dash.depositing.authorAwad, Mark M.en_US
dc.date.available2017-12-06T16:20:21Z
dc.identifier.doi10.18632/oncotarget.21182*
dash.authorsorderedfalse
dash.contributor.affiliatedAwad, Mark
dash.contributor.affiliatedChiarle, Roberto
dash.contributor.affiliatedSholl, Lynette
dash.contributor.affiliatedJanne, Pasi


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record